March 22nd 2023
Patients with metastatic or recurrent locally advanced Merkel cell carcinoma can now receive treatment with retifanlimab-dlwr following its accelerated approval by the FDA.
Novel, Immune Therapies Promising in Nonmelanoma Skin Cancers
March 9th 2017Treatment of keratinocyte carcinomas such as basal cell carcinoma and cutaneous squamous cell carcinoma with PD-1 checkpoint inhibitors and targeted agents warrant further investigation, according to recently published studies.
Chemical Compound May Help Reduce the Spread of Melanoma
January 17th 2017There is a lot of interest in a new treatment that kills approximately 90% of melanoma cancer cells, an astounding accomplishment for Richard Neubig, MD, PhD, who serves as chairperson of pharmacology toxicology at Michigan State University.
Viral Oncoprotien Antibodies May Help Detect Merkel Cell Carcinoma Recurrence
December 13th 2016Scientists have found a way to detect earlier if Merkel cell carcinoma (MCC) is recurring in patients. They have published a paper in the journal Cancer demonstrating how an immune system marker may be able to outperform and supplement imaging studies for recurrence of MCC.
Predicting Patient Outcomes With Mathematical Modeling in Virtual Clinical Trials
November 22nd 2016Researchers from Moffitt Cancer Center’s Integrated Mathematical Oncology (IMO) Department are overcoming some of the limitations of common preclinical experiments and clinical trials by studying cancer through mathematical modeling.
Immune, Targeted Therapies Plus Radiation Ups Survival in Melanoma Patients With Brain Metastases
September 30th 2016Researchers at Moffitt Cancer Center in Tampa, Fla., demonstrated how novel immune and targeted therapies with radiation therapy may improve the outcomes of patients with melanoma who have brain metastases.
Encorafenib and Binimetinib Combo May Help Improve Survival in Patients With BRAF-Mutant Melanoma
September 28th 2016Combining the BRAF inhibitor encorafenib with the MEK inhibitor binimetinib may significantly improve progression-free survival in BRAF mutant melanoma, according to a new phase III trial.